Do analysts rate BTAI or ENTO?

BioXcel Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 1,197.94%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe BioXcel Therapeutics is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ENTO or EVAX?

Evaxion A/S has a consensus target price of $11.00, indicating a potential upside of 275.43%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts clearly believe Evaxion A/S is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is ENTO or EVAX more profitable?

Evaxion A/S's return on equity of -73.56% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -461.02% -14.72% Evaxion A/S N/A -73.56% -37.45%

Do analysts rate ENTO or VYNE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Does the media refer more to ENTO or VYNE?

In the previous week, VYNE Therapeutics had 6 more articles in the media than Entero Therapeutics. MarketBeat recorded 7 mentions for VYNE Therapeutics and 1 mentions for Entero Therapeutics. VYNE Therapeutics' average media sentiment score of 0.05 beat Entero Therapeutics' score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VYNE Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ENTO or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, ENTO or ALVR?

Entero Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is ENTO or ALVR more profitable?

AlloVir's return on equity of -71.03% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -461.02% -14.72% AlloVir N/A -71.03% -61.27%

Do analysts rate ENTO or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Entero Therapeutics (ENTO) Competitors

$3.04 -0.31 (-9.25%)

As of 07/24/2026

Compare

ENTO vs. BTAI, EVAX, VYNE, ALVR, and TXMD

Should you buy Entero Therapeutics stock or one of its competitors? MarketBeat compares Entero Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entero Therapeutics include BioXcel Therapeutics (BTAI), Evaxion A/S (EVAX), VYNE Therapeutics (VYNE), AlloVir (ALVR), and TherapeuticsMD (TXMD). These companies are all part of the "pharmaceutical products" industry.

How does Entero Therapeutics compare to BioXcel Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

BioXcel Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

BioXcel Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 1,197.94%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe BioXcel Therapeutics is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Entero Therapeutics has lower revenue, but higher earnings than BioXcel Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$680K	38.48	-$69.90M	-$5.75	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

In the previous week, BioXcel Therapeutics and BioXcel Therapeutics both had 1 articles in the media. BioXcel Therapeutics' average media sentiment score of 1.87 beat Entero Therapeutics' score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
BioXcel Therapeutics	Very Positive
Entero Therapeutics	Neutral

Entero Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
Entero Therapeutics	N/A	-461.02%	-14.72%

Summary

BioXcel Therapeutics beats Entero Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Entero Therapeutics compare to Evaxion A/S?

Entero Therapeutics (NASDAQ:ENTO) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, Entero Therapeutics and Entero Therapeutics both had 1 articles in the media. Evaxion A/S's average media sentiment score of 1.89 beat Entero Therapeutics' score of 0.00 indicating that Evaxion A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Evaxion A/S	Very Positive

Evaxion A/S's return on equity of -73.56% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
Evaxion A/S	N/A	-73.56%	-37.45%

Evaxion A/S has higher revenue and earnings than Entero Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
Evaxion A/S	$7.53M	3.25	-$7.71M	-$1.47	N/A

Evaxion A/S has a consensus target price of $11.00, indicating a potential upside of 275.43%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts clearly believe Evaxion A/S is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Summary

Evaxion A/S beats Entero Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to VYNE Therapeutics?

Entero Therapeutics (NASDAQ:ENTO) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Entero Therapeutics has higher earnings, but lower revenue than VYNE Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
VYNE Therapeutics	$454K	37.43	-$26.48M	-$0.38	N/A

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, VYNE Therapeutics had 6 more articles in the media than Entero Therapeutics. MarketBeat recorded 7 mentions for VYNE Therapeutics and 1 mentions for Entero Therapeutics. VYNE Therapeutics' average media sentiment score of 0.05 beat Entero Therapeutics' score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entero Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VYNE Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the broader market.

Entero Therapeutics has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

Summary

VYNE Therapeutics beats Entero Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to AlloVir?

Entero Therapeutics (NASDAQ:ENTO) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

In the previous week, Entero Therapeutics had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Entero Therapeutics and 0 mentions for AlloVir. Entero Therapeutics' average media sentiment score of 0.00 equaled AlloVir'saverage media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
AlloVir	Neutral

AlloVir's return on equity of -71.03% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
AlloVir	N/A	-71.03%	-61.27%

Entero Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Entero Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Entero Therapeutics beats AlloVir on 6 of the 10 factors compared between the two stocks.

How does Entero Therapeutics compare to TherapeuticsMD?

Entero Therapeutics (NASDAQ:ENTO) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

TherapeuticsMD has a net margin of 5.34% compared to Entero Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
TherapeuticsMD	5.34%	0.32%	0.23%

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

TherapeuticsMD has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
TherapeuticsMD	$3.02M	7.89	-$570K	$0.06	34.33

In the previous week, Entero Therapeutics and Entero Therapeutics both had 1 articles in the media. TherapeuticsMD's average media sentiment score of 1.87 beat Entero Therapeutics' score of 0.00 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Entero Therapeutics	Neutral
TherapeuticsMD	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TherapeuticsMD beats Entero Therapeutics on 10 of the 11 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTO vs. The Competition

Export

Metric	Entero Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.83M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.80	21.48	27.14	23.64
Price / Sales	N/A	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	-1.24	7.88	10.28	6.07
Net Income	-$18.06M	$23.86M	$3.60B	$331.99M
7 Day Performance	-20.42%	-3.82%	-1.27%	-0.63%
1 Month Performance	-31.22%	-2.61%	-0.37%	-2.00%
1 Year Performance	111.55%	32.79%	18.30%	13.62%

Entero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTO Entero Therapeutics	0.0124 of 5 stars	$3.04 -9.3%	N/A	+130.7%	$4.83M	N/A	N/A	9	News Coverage Gap Up
BTAI BioXcel Therapeutics	2.7689 of 5 stars	$0.83 -4.5%	$11.00 +1,223.7%	-51.0%	$25.29M	$640K	N/A	90	Positive News
EVAX Evaxion A/S	3.2483 of 5 stars	$3.04 -2.7%	$11.00 +262.3%	+8.1%	$25.27M	$7.53M	N/A	60
VYNE VYNE Therapeutics	1.0209 of 5 stars	$0.75 -2.7%	N/A	-62.0%	$25.05M	$570K	N/A	30	News Coverage Short Interest Increase Gap Down
ALVR AlloVir	N/A	$4.82 +5.9%	N/A	+46.9%	$24.31M	N/A	N/A	110	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTO) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entero Therapeutics (ENTO) Competitors

ENTO vs. BTAI, EVAX, VYNE, ALVR, and TXMD

How does Entero Therapeutics compare to BioXcel Therapeutics?

Summary

How does Entero Therapeutics compare to Evaxion A/S?

Summary

How does Entero Therapeutics compare to VYNE Therapeutics?

Summary

How does Entero Therapeutics compare to AlloVir?

Summary

How does Entero Therapeutics compare to TherapeuticsMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTO vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entero Therapeutics (ENTO) Competitors

ENTO vs. BTAI, EVAX, VYNE, ALVR, and TXMD

How does Entero Therapeutics compare to BioXcel Therapeutics?

Which has more volatility & risk, BTAI or ENTO?

Do analysts rate BTAI or ENTO?

Do institutionals & insiders hold more shares of BTAI or ENTO?

Which has better earnings & valuation, BTAI or ENTO?

Does the media prefer BTAI or ENTO?

Is BTAI or ENTO more profitable?

Summary

How does Entero Therapeutics compare to Evaxion A/S?

Does the media favor ENTO or EVAX?

Is ENTO or EVAX more profitable?

Which has stronger earnings and valuation, ENTO or EVAX?

Do analysts rate ENTO or EVAX?

Do insiders & institutionals hold more shares of ENTO or EVAX?

Which has more risk and volatility, ENTO or EVAX?

Summary

How does Entero Therapeutics compare to VYNE Therapeutics?

Which has better earnings and valuation, ENTO or VYNE?

Do institutionals & insiders have more ownership in ENTO or VYNE?

Does the media refer more to ENTO or VYNE?

Do analysts rate ENTO or VYNE?

Which has more risk & volatility, ENTO or VYNE?

Is ENTO or VYNE more profitable?

Summary

How does Entero Therapeutics compare to AlloVir?

Does the media favor ENTO or ALVR?

Is ENTO or ALVR more profitable?

Which has higher valuation & earnings, ENTO or ALVR?

Which has more risk & volatility, ENTO or ALVR?

Do analysts prefer ENTO or ALVR?

Do institutionals and insiders have more ownership in ENTO or ALVR?

Summary

How does Entero Therapeutics compare to TherapeuticsMD?

Which has more volatility and risk, ENTO or TXMD?

Is ENTO or TXMD more profitable?

Do insiders and institutionals have more ownership in ENTO or TXMD?

Which has stronger earnings & valuation, ENTO or TXMD?

Does the media refer more to ENTO or TXMD?

Do analysts rate ENTO or TXMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTO vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools